Immunity for Health

IfH Symposium: Innovations in Antibody-Based Biologics

11 Jun 2026 | Landmark Building, UZ Brussels, Belgium

Ghent University - provaxs

Academic / Research Institution

www.provaxs.comMerelbeke, Belgium
2 profile visits

About

Your preferred academic partner

We can become your preferred academic partner and support your innovation-projects in animal health. We combine scientific expertise, knowledge and know-how on animal health with an entrepreneurial organisation of scientists and experienced tech-transfer professionals. Not only that, but thanks to the Industrial Research Fund of Ghent University we have access to proof-of-concept funding, open for collaboration with industry.

Flexibility and tailor-made partnerships

We are receptive to all types of collaborations and partnerships:

  • out-licensing and development of our UGent-technologies towards the final product

  • research collaboration on a single project, either bilateral or in a research consortium

  • strategic partnerships with a specific focus/topic.

All our collaborations and partnerships are supported by a professional business development/tech-transfer team and are based on solid tailor-made agreements on confidentiality, ownership, and exploitation of results.

RESEARCH AND DEVELOPMENT

Preclinical researchImmunotherapy developmentCell and Gene therapyVaccine developmentmRNA vaccinesVaccine platformsVaccine adjuvantsVaccine delivery systemsBiomarker discoveryStem cellsTranslational researchInfectious diseases modelling and epidemiologyDiagnostics

CLINICAL DEVELOPMENT AND TRIALS

Clinical trials

DIGITAL HEALTH AND TECHNOLOGY

Digital health toolsNanotechnologyMedical devicesRobotics / AI / Big Data

THERAPEUTIC AREAS

Infectious diseasesOncologyImmunologyAutoimmune disordersRespiratory diseasesAllergiesCardiovascular diseasesNeurodegenerative diseases

HEALTH SECTOR

Animal health

Representatives

Business Development Manager

Ghent University - provaxs

Marketplace (3)

  • Expertise

    Entry portal through the intestinal barrier

    Antibody-based targeting to APN for controlled transfer of biologicals through the intestinal (mucosal) barrier.

    • Immunology
    • Immunotherapy
    • Vaccine Development
    • Infectious Diseases
    Author

    Business Development Manager at Ghent University - provaxs

    Merelbeke, Belgium

  • Service

    Bridging veterinary and human health through translational research

    UGent PROVAXS and the Faculty of Veterinary Medicine accelerate translational research through advanced non-rodent animal models and veterinary patients, enabling predictive pre-clinical studies that strengthen the path toward human clinical applications.

    • Human health
    • Animal health
    • Research & Development
    Author

    Business Development Manager at Ghent University - provaxs

    Merelbeke, Belgium

  • Expertise

    Controlled expression of sa-mRNA

    A novel enhanced saRNA platform from Ghent University enables prolonged and efficient therapeutic protein expression with reduced cellular toxicity, supporting safer and more effective vaccines, immunotherapies, and RNA-based medicines.

    • Immunology
    • Immunotherapy
    • Clinical Trials
    • Preclinical trials
    • Vaccine Development
    Author

    Business Development Manager at Ghent University - provaxs

    Merelbeke, Belgium